318.22
-12.37 (-3.74%)
| Previous Close | 330.59 |
| Open | 318.50 |
| Volume | 436,458 |
| Avg. Volume (3M) | 616,268 |
| Market Cap | 8,862,691,328 |
| Price / Sales | 953.14 |
| Price / Book | 9.80 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Operating Margin (TTM) | -2,868.84% |
| Diluted EPS (TTM) | -10.66 |
| Quarterly Revenue Growth (YOY) | 1,349.10% |
| Total Debt/Equity (MRQ) | 0.24% |
| Current Ratio (MRQ) | 8.44 |
| Operating Cash Flow (TTM) | -163.91 M |
| Levered Free Cash Flow (TTM) | -90.04 M |
| Return on Assets (TTM) | -39.95% |
| Return on Equity (TTM) | -63.56% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Praxis Precision Medicines, Inc | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.88 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.16% |
| % Held by Institutions | 122.02% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 1,245.00 (HC Wainwright & Co., 291.24%) | Buy |
| Median | 700.00 (119.97%) | |
| Low | 130.00 (Wedbush, -59.15%) | Sell |
| Average | 674.18 (111.86%) | |
| Total | 9 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 319.32 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 500.00 (57.12%) | Buy | 342.71 |
| Baird | 20 Feb 2026 | 433.00 (36.07%) | Buy | 335.28 |
| Truist Securities | 20 Feb 2026 | 700.00 (119.97%) | Buy | 335.28 |
| Wedbush | 20 Feb 2026 | 130.00 (-59.15%) | Sell | 335.28 |
| 12 Jan 2026 | 95.00 (-70.15%) | Sell | 275.74 | |
| Wells Fargo | 20 Feb 2026 | 305.00 (-4.15%) | Hold | 335.28 |
| 02 Feb 2026 | 282.00 (-11.38%) | Hold | 309.11 | |
| Guggenheim | 10 Feb 2026 | 800.00 (151.40%) | Buy | 320.48 |
| Needham | 04 Feb 2026 | 510.00 (60.27%) | Buy | 303.34 |
| HC Wainwright & Co. | 30 Jan 2026 | 1,245.00 (291.24%) | Buy | 314.00 |
| Piper Sandler | 28 Jan 2026 | 1,200.00 (277.10%) | Buy | 309.92 |
| BTIG | 29 Dec 2025 | 843.00 (164.91%) | Buy | 304.58 |
| Oppenheimer | 15 Dec 2025 | 750.00 (135.69%) | Buy | 276.40 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |